AdvanSix's second quarter is a print that demands two readings. The first says a vertically integrated U.S. nylon-and-fertilizer company is in trouble: net income fell 90% year-over-year, gross margin compressed 690 basis points to 7.4%, and the stock dropped 18% in a single session on the print. The second says almost the opposite. Sales rose 3% on a 18% pricing gain that mostly passed through $1.4 billion of higher benzene, propylene and sulfur costs - proof that the formula-pricing architecture still works. Volume fell 15%, but almost entirely in Plant Nutrients, where a weak spring planting season and a 16% ammonium sulfate volume decline dragged the segment into the red. Adjusted EBITDA margin compressed to 7.6% from 13.6%, but the comparison absorbed a $26 million insurance settlement that landed in last year's first quarter and never recurred; stripped of that one-time, the year-over-year deterioration is real but more measured. The cash story is genuinely bifurcated. The company burned $61.9 million of free cash flow in the first half - driven by a $20.7 million Q2 capex bill and a $12.5 million dividend run-rate - but operating cash flow recovered to $10 million in the second quarter from negative territory in Q1, and management's full-year guidance hinges on sequential improvement in the second half from a lower capex run-rate and the Q4 ammonium sulfate pre-buy program.
The interesting move is in the stock, not the numbers. At a reference price of $16.53 (August 13, 2026), AdvanSix trades at roughly 0.5x trailing sales, 5.8x trailing adjusted EBITDA ex the prior-year insurance proceeds, and 7.3x the $2.28 of adjusted EPS it earned in 2025. The dividend, unchanged at $0.16 per quarter, yields 3.9%. The market is now pricing the company for a base case where Plant Nutrients stays weak, Chemical Intermediates and Nylon Solutions hold their mid-cycle margins, and the leverage ticks up as cash flow remains pressured. What it is NOT pricing is the second-half turn management is forecasting, or the fact that a $62 million buyback authorization has been sitting untouched since June 2024 while the share price has more than halved from its 2025 high. The thesis is a bet on sequential cash-flow recovery from a sub-trough multiple - a classic cyclical bottom-fishing setup whose central question is whether ammonium sulfate demand normalizes by Q4.